<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ911217-0140</DOCNO><DOCID>911217-0140.</DOCID><HL>   Technology:   Deprenyl Research New Drug</HL><DATE>12/17/91</DATE><SO>WALL STREET JOURNAL (J), PAGE B4</SO><CO>   DEPLF</CO><MS>CONSUMER NON-CYCLICAL (NCY)</MS><IN>DRUG MANUFACTURERS (DRG)</IN><NS>NEW PRODUCTS andamp; SERVICES (PDT)SCIENCE andamp; TECHNOLOGY (SCN)</NS><RE>CANADA (CN)NORTH AMERICA (NME)</RE><LP>   TORONTO -- Deprenyl Research Ltd., seeking approval forthe test of its Alzene drug in the treatment of Alzheimer'sdisease, said it filed a new drug application with theCanadian government.   Deprenyl said it plans to carry out two sets of tests inCanada, one to measure the effect of Alzene in restoringmemory in Alzheimer's patients and the other to test thedrug's effect in improving the memory of normal adults.</LP><TEXT>   Deprenyl's main product is Eldepryl, a medication used totreat Parkinson's disease.</TEXT></DOC>